Skip to content
Screener

EPS (Diluted) at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$1.64-18.0%
Stryker logo
StrykerSYK
$3.30+44.1%
IAR
Integra LifeSciencesIART
$0.06+101%
Solventum logo
SolventumSOLV
$0.53+3.9%
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
-$0.39-8.3%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
-$0.32-45.5%

Other financials

Income statement

See full
Revenue$28.1M+9.0%
Gross profit$26.2M+9.6%
Operating income$1.8M-28.4%
Net income-$452.9K+77.5%

Balance sheet

See full
Cash & equivalents$15.4M-9.1%
Total debt$48.5M+6.8%
Total equity$7.9M-77.6%
Total assets$69.1M-30.0%

Cash flow

See full
Operating cash flow-$2.5M-23.3%
CapEx$5.3K-99.7%
Free cash flow-$2.5M+32.6%

Valuation

See full
Market cap$320.48M+16.6%
Enterprise value$353.59M+15.0%
P/S2.9×+0.2×

Profitability

See full
Gross margin93%+1.3pp
Operating margin7.7%+1.1pp
Net margin-29.2%-63.4pp
FCF margin-9.8%-3.5pp

Returns & leverage

See full
Return on equity-147.7%-187pp
Debt / equity6.1×+4.8×
Current ratio2.6×+0.3×

Where this comes from

Reported directly by Sanara MedTech Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Sanara MedTech Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 5:08 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001493152-26-037176
Line item2026 / Three Months Ended June 30,2025 / Three Months Ended June 30,2026 / Six Months Ended June 30,2025 / Six Months Ended June 30,
Discontinued operations-(0.29)-(0.63)
Net income (loss) per share of common stock, basic$(0.05)$(0.23)-$(0.64)
Net income (loss) per share, diluted:
Continuing operations$(0.05)$0.05-$(0.01)
Discontinued operations-(0.28)-(0.63)
Net income (loss) per share of common stock, diluted$(0.05)$(0.23)-$(0.64)
Weighted average number of common shares outstanding, basic8,662,6718,612,9868,732,8498,591,663
Weighted average number of common shares outstanding, diluted8,662,6718,927,0608,732,8498,591,663

Document

FAQ

What is Sanara MedTech Inc.'s EPS (diluted)?
Sanara MedTech Inc. (SMTI) reported EPS (diluted) of -$0.05 in Q2 2026.
How has Sanara MedTech Inc.'s EPS (diluted) changed year-over-year?
Sanara MedTech Inc.'s EPS (diluted) increased by 78.3% year-over-year, from -$0.23 to -$0.05.
What is the long-term trend for Sanara MedTech Inc.'s EPS (diluted)?
Over 4 years (2021 to 2025), Sanara MedTech Inc.'s EPS (diluted) has grown at a 41.7% compound annual growth rate (CAGR), from -$1.08 to -$4.36.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Sanara MedTech Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude